Modelling costs of interventional pulmonary embolism treatment: implications of US trends for a European healthcare system
Authors:
- Katharina MohrKMKatharina Mohr
- Thomas NeusiusTNThomas Neusius
- Rachel P RosovskyRRRachel P Rosovsky
- John M MoriartyJMJohn M Moriarty
- Kenneth RosenfieldKRKenneth Rosenfield
- Christina AbeleCAChristina Abele
- Ioannis T FarmakisIFIoannis T Farmakis
- Karsten KellerKarsten Keller
- Stefano BarcoSBStefano Barco
- Richard N ChannickRCRichard N Channick
Open Access
- 13 February 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 13 (6) , 501-505
Abstract
Catheter-directed treatment (CDT) of acute pulmonary embolism (PE) is entering a growth phase in Europe following a steady increase in the United States (US) in the past decade, but the potential economic impact on European healthcare systems remains unknown. We built two statistical models for the monthly trend of proportion of CDT among patients with severe (intermediate- or high-risk) PE in the US. The conservative model was based on admission data from the National Inpatient Sample (NIS) 2016-2020, and the model reflecting increasing access to advanced treatment from the PERTTM national quality assurance database registry 2018-2021. By applying these models to the forecast of annual PE-related hospitalizations in Germany, we calculated the annual number of severe PE cases and the expected increase in CDT use for the period 2025-2030. The NIS-based model yielded a slow increase, reaching 3.1% (95% CI 3.0-3.2%) among all hospitalizations with PE in 2030; in the PERT-based model, increase would be steeper, reaching 8.7% (8.3-9.2%). Based on current reimbursement rates, we estimated an increase of annual costs for PE-related hospitalizations in Germany ranging from 15.3 to 49.8 million euros by 2030. This calculation does not account for potential cost savings, including those from reduced length of hospital stay. Our approach and results, which may be adapted to other European healthcare systems, provide a benchmark for healthcare costs expected to result from CDT. Data from ongoing trials on clinical benefits and cost savings are needed to determine cost-effectiveness and inform reimbursement decisions.Keywords
Funding Information
- University Medical Centre Mainz
This publication has 13 references indexed in Scilit:
- Temporal trends in the utilization of advanced therapies among patients with acute pulmonary embolism: insights from a national databaseEuropean Heart Journal: Acute Cardiovascular Care, 2023
- Interventional treatment and multidisciplinary management strategies for acute pulmonary embolismDie Kardiologie, 2023
- Interventional therapies for pulmonary embolismNature Reviews Cardiology, 2023
- Pulmonary embolism response team (PERT) implementation and its clinical value across countries: a scoping review and meta-analysisClinical Research in Cardiology, 2022
- Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO studyAmerican Heart Journal, 2022
- Catheter directed compared to systemically delivered thrombolysis for pulmonary embolism: a systematic review and meta-analysisJournal of Thrombosis and Thrombolysis, 2021
- Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart AssociationCirculation, 2019
- 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)European Heart Journal, 2019
- Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in GermanyEuropean Heart Journal, 2019
- Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysisJournal of Thrombosis and Thrombolysis, 2018